• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

OMRF is an independent, nonprofit biomedical research institute dedicated to discoveries that make a difference.

  • About
    • General Information
    • Disease Research
    • Education & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti-Aging Studies
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Tax Credit
    • Planned Giving
    • Vehicle Donations
    • Why We Give
    • Your Gift at Work
    • Donor Recognition
    • Contact
Home - OMRF News - Archives for Manu Nair

Manu Nair

New use for OMRF brain cancer treatment could extend lives

December 18, 2019

In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.

Filed Under: News, Technology Ventures News Tagged With: battiste, brain cancer, cancer, center, chemo, drug, glioblastoma, James, Manu Nair, newsok, OKC, Oklahoma Medical Research Foundation, OKN-007, OMRF, ou, OUHSC, patient, Rheal, scientist-news, stephenson, technology ventures, temodar, therapy, Towner, treatment, university of oklahoma

Oblato acquires all rights to glioblastoma drug from OMRF

October 29, 2018

Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.

Filed Under: News, Technology Ventures News Tagged With: 007, americans, brain, cancer, clinical, deadly, diagnosis, drug, edward kennedy, Gtree, james battiste, john mccain, Manu Nair, mike schuster, model, news, Norman, Oblato, Oklahoma Medical Research Foundation, okn, OKN-007, OMRF, Rheal, rheal towner, robert floyd, scientist-news, Stephenson Cancer Center, technology, testing, therapy, Towner, treatment, trial, tumor, university of oklahoma

OMRF enters into a license agreement with Shanghai RAAS Blood Products

February 13, 2018

OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.

Filed Under: News, Technology Ventures News Tagged With: Activated Protein C, agreement, americans, antibody, apc, approval, blood, blood clots, breakthrough, CDC, Charles, charles esmon, China, chuck esmon, deal, death, disorder, drug, Esmon, forbes, hemophilia, injuries, innovation, license, Manu Nair, new, news, newsok, novel, OKC, Oklahoma City, Oklahoma Medical Research Foundation, OMRF, products, research, rights, scientist-news, sepsis, shanghai raas, technology, trauma, traumatic bleeding, treatment

Pet Rx: Can human health research benefit our four-legged friends?

May 16, 2017

Health advancements made at OMRF could translate to better health for your pets.

Filed Under: News, Technology Ventures News Tagged With: animal, biomedical, cats, dogs, economic, health, healthcare, Manu Nair, market, metro, newsok, OKC, Oklahoma City, Oklahoma Medical Research Foundation, OMRF, pet, pet products association, research, science, segment, vet, veterinarian

Eisai, OMRF enter autoimmune disease research collaboration

October 27, 2016

The project is focused on lupus, which affects up to 1.5 million Americans.

Filed Under: News, Technology Ventures News Tagged With: andover innovative medicines, arthritis, biomedical, clinical, clinical trials, collaboration, dna sequencing, eisai, Gaffney, genes, genetic, human immune response, immunology, initiative, lupus, Lupus Foundation of America, Manu Nair, molecules, OKC, Oklahoma Medical Research Foundation, OMRF, partner, pat gaffney, pathways, patients, patrick, research, resources, scientist-news, significant, testing

Biotech company acquires OMRF brain cancer drug

February 15, 2016

Agreement will expand clinical trials of glioblastoma drug

Filed Under: News Tagged With: brain cancer, brain tumor, cancer, clinical trial, glioblastoma, glioma, Gtree, GtreeBNT, investigational drug, Manu Nair, Oblato, OKN-007, pharmaceuticals, Rheal, scientist-news, Towner

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Before Footer

EEO/AA Employer/Vet/Disabled

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayGive Smart OKCTop Workplace